First Class Metals - Warrant Conversion & Issue of Equity
Released
RNS Number : 4319J
First Class Metals PLC
("First Class Metals" or the "Company")
Exercise of Warrants and Issue of Equity
First Class Metals PLC (LSE:FCM) announces that it has received a notice to exercise warrants over a total of 160,000 Ordinary Shares (the "Warrant Shares"), for which funds of GBP17,250 have been received by the Company.
Application will be made to the Financial Conduct Authority ("FCA") for admission of the Ordinary Shares to the standard listing segment of the Official List and to trading on the London Stock Exchange's Main Market for listed securities, with admission and dealings in the new shares expected to take place from 8.00am on 20thDecember 2022.
Following Admission, the Company's issued share capital will consist of 68,733,707 Ordinary Shares with voting rights. This figure of 68,733,707 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they require to notify their interest in, or a change to their interest in, the share capital of the Company under the UK Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
For further information, please contact:
First Class Metals PLC
James Knowles, Executive Chairman | 07488 362641 | |
Marc J Sale, CEO | 07711 093532 | |
Ayub Bodi, Executive Director | 07860 598086 |
First Equity Limited
(Financial Adviser & Broker)
Jason Robertson/ Jonathan Brown 02073742212
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the
Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the
use the personal data you provide us, please see our Privacy Policy.
END
IOEQLLFFLLLFFBF
Share your feedback
Discover